indie Semiconductor delivered a rare combination this week — a revenue beat and an EPS miss on the same print — and the stock's reaction told you exactly where the weight of positioning lies.
Short interest has been the defining feature of the INDI story for months, and nothing this week changed that. At 32.3% of the free float, it is one of the most heavily shorted names in the semiconductor universe. The ORTEX short score clocks in at 86, in the top percentile for squeeze-risk indicators, and days-to-cover have stretched to nearly 25 — meaning shorts would need the better part of a month's typical trading volume to exit cleanly. What makes the setup even more constrained is the lending market: every share available to borrow has been lent out. Availability has been at zero for virtually the entire past year, the longest stretch of maximum tightness in the 52-week window. Cost to borrow has eased considerably — down 39% over the past month to roughly 7.1% — but the direction here is a relief valve for existing shorts, not an invitation for new ones. The borrowing pool is simply empty.
Options positioning tells a different story to the shorts. The put/call ratio came in at 0.21 on Friday, well below its 20-day average of 0.25, sitting near the low end of its 52-week range and more than a standard deviation below the mean. That is an aggressively call-heavy skew — options traders are leaning bullish, not defensive. After the stock rallied nearly 49% in the prior month into earnings, that call-heavy positioning could reflect either optimism about the Q2 guide or continued momentum chasing. The juxtaposition with 32% SI and fully depleted borrow availability creates a notably charged setup.
The print itself was mixed but not disastrous. Q1 adjusted EPS came in at -$0.06, beating the most bearish estimates but still missing consensus. Revenue of $55.5 million was a small beat. Q2 guidance of $59–65 million straddled the $63 million analyst estimate — wide enough to keep both bulls and bears well-stocked with arguments. UBS reacted immediately, maintaining its Neutral rating but lifting its price target from $4.25 to $4.75. That leaves the mean Street target at $6.13, roughly 43% above the current $4.30 close — meaningful upside on paper, though the bull case from Benchmark (target $8.00) and the bear case both highlight the same core tension: the company is nudging toward profitability but remains loss-making, and the $60 million divestiture overhang continues to cloud the revenue outlook. The EPS 12-month forward year-on-year improvement ranks in the 95th percentile of the universe, which tells you estimates are moving sharply in the right direction even if the current figures are still negative.
The institutional register shows active money moving in, not out. Elemental Capital Partners added 4.7 million shares in Q1, State Street added over 3.2 million, and Wasatch Advisors put on 2.2 million — all in the quarter through March. PRIMECAP remains the largest holder at 14%. Counterbalancing that is the founder. President Ichiro Aoki sold roughly 250,000 shares across five separate transactions in late April and early May, raising approximately $1 million at prices between $3.54 and $4.40. The pace of selling is systematic rather than panicked — structured, small tranches as the stock recovered — but the direction is worth noting given the broader institutional buying.
Peers had a strong week relative to INDI's 2% slide. SYNA surged 30%, KOPN jumped 26%, and CEVA added 14.5%. MCHP gained 5.5%. INDI lagged the group meaningfully, even as the semiconductor tape broadly recovered.
With the stock down 4.2% on Friday post-earnings and another event flagged on May 14, the week ahead will test whether 32% short interest at zero availability produces any covering pressure — or whether the Q2 guide's wide range and persistent losses keep shorts anchored.
See the live data behind this article on ORTEX.
Open INDI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
